Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Bausch Health Companies Inc. or Dr. Reddy's Laboratories Limited because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited compare based on key financial metrics to determine which better meets your investment needs.

About Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Latest Pharmaceuticals and Bausch Health Companies Inc., Dr. Reddy's Laboratories Limited Stock News

As of September 4, 2026, Bausch Health Companies Inc. had a $2.5 billion market capitalization, compared to the Pharmaceuticals median of $672.4 million. Bausch Health Companies Inc.’s stock is down 5.6% in 2026, up 3.8% in the previous five trading days and down 9.02% in the past year.

Currently, Bausch Health Companies Inc. does not have a price-earnings ratio. Bausch Health Companies Inc.’s trailing 12-month revenue is $10.9 billion with a -10.1% net profit margin. Year-over-year quarterly sales growth most recently was 12.7%. Analysts expect adjusted earnings to reach $4.466 per share for the current fiscal year. Bausch Health Companies Inc. does not currently pay a dividend.

As of September 4, 2026, Dr. Reddy's Laboratories Limited had a $10.1 billion market cap, putting it in the 77th percentile of all stocks. Dr. Reddy's Laboratories Limited’s stock is down 14.7% in 2026, down 1.7% in the previous five trading days and down 15.41% in the past year.

Currently, Dr. Reddy's Laboratories Limited’s price-earnings ratio is 28.5. Dr. Reddy's Laboratories Limited’s trailing 12-month revenue is $3.5 billion with a 10.0% net profit margin. Year-over-year quarterly sales growth most recently was -14.3%. There are no analysts providing consensus earnings estimates for the current fiscal year. Dr. Reddy's Laboratories Limited currently has a 0.7% dividend yield.

How We Compare Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited’s Quality Grades

Company	Ticker	Quality
Bausch Health Companies Inc.	BHC	B
Dr. Reddy's Laboratories Limited	RDY	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Bausch Health Companies Inc. has a Quality Score of 79, which is Strong. Dr. Reddy's Laboratories Limited has a Quality Score of 80, which is Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited have a grade of B. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited’s Momentum Grades

Company	Ticker	Momentum
Bausch Health Companies Inc.	BHC	C
Dr. Reddy's Laboratories Limited	RDY	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Bausch Health Companies Inc. has a Momentum Score of 55, which is Average. Dr. Reddy's Laboratories Limited has a Momentum Score of 24, which is Weak.

The Momentum Stock Winner: No Clear Winner

Neither Bausch Health Companies Inc. or Dr. Reddy's Laboratories Limited has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Bausch Health Companies Inc. or Dr. Reddy's Laboratories Limited is the better investment when it comes to momentum.

Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Bausch Health Companies Inc.	BHC	C
Dr. Reddy's Laboratories Limited	RDY	na

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Bausch Health Companies Inc. has a Earnings Estimate Score of 48, which is Neutral. Dr. Reddy's Laboratories Limited does not have a meaningful Earnings Estimate Score.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Bausch Health Companies Inc. or Dr. Reddy's Laboratories Limited has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Bausch Health Companies Inc. or Dr. Reddy's Laboratories Limited is the better investment when it comes to estimate revisions.

Other Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited Grades

In addition to Momentum, Quality and Estimate Revisions, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Bausch Health Companies Inc. or Dr. Reddy's Laboratories Limited Stock?

Overall, Bausch Health Companies Inc. stock has a Momentum Score of 55, Estimate Revisions Score of 48 and Quality Score of 79.

Dr. Reddy's Laboratories Limited stock has a Momentum Score of 24, Estimate Revisions Score of and Quality Score of 80.

Comparing Bausch Health Companies Inc. and Dr. Reddy's Laboratories Limited’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.